Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Echols

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Expert Review of Anti-Infective Therapy|December 23, 2021
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studiesThomas P Lodise, Matteo Bassetti, Ricard Ferrer, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|May 30, 2023
<i>In Vitro</i> Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019Mark G Wise, James A Karlowsky, Meredith A Hackel, et al.
Open Forum Infectious Diseases|October 14, 2017
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i>Bin Cai, Roger Echols, Glenn Magee, et al.
The Lancet. Infectious Diseases|December 5, 2018
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trialSimon Portsmouth, David van Veenhuyzen, Roger Echols, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2021
Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumoniaTakayuki Katsube, David P Nicolau, Keith A Rodvold, et al.
The Journal of Antimicrobial Chemotherapy|August 12, 2021
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumoniaTakayuki Katsube, David P Nicolau, Keith A Rodvold, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2022
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic RabbitsVidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infectionsScott Van Wart, Luann Phillips, Elizabeth A Ludwig, et al.
The Journal of Infectious Diseases|January 17, 2019
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaGeorge H Talbot, Anita Das, Stephanie Cush, et al.
The Lancet. Infectious Diseases|October 15, 2020
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialRichard G Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Expert Review of Anti-Infective Therapy|December 23, 2021
All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studiesThomas P Lodise, Matteo Bassetti, Ricard Ferrer, et al.
Microbial Drug Resistance (Larchmont, N.Y.)|May 30, 2023
<i>In Vitro</i> Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014-2019Mark G Wise, James A Karlowsky, Meredith A Hackel, et al.
Open Forum Infectious Diseases|October 14, 2017
Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States Predominated by <i>Acinetobacter baumannii</i> and <i>Pseudomonas aeruginosa</i>Bin Cai, Roger Echols, Glenn Magee, et al.
The Lancet. Infectious Diseases|December 5, 2018
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trialSimon Portsmouth, David van Veenhuyzen, Roger Echols, et al.
The Journal of Antimicrobial Chemotherapy|September 17, 2021
Erratum to: Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumoniaTakayuki Katsube, David P Nicolau, Keith A Rodvold, et al.
The Journal of Antimicrobial Chemotherapy|August 12, 2021
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumoniaTakayuki Katsube, David P Nicolau, Keith A Rodvold, et al.
Antimicrobial Agents and Chemotherapy|September 26, 2022
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic RabbitsVidmantas Petraitis, Ruta Petraitiene, Povilas Kavaliauskas, et al.
Antimicrobial Agents and Chemotherapy|November 25, 2004
Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infectionsScott Van Wart, Luann Phillips, Elizabeth A Ludwig, et al.
The Journal of Infectious Diseases|January 17, 2019
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaGeorge H Talbot, Anita Das, Stephanie Cush, et al.
The Lancet. Infectious Diseases|October 15, 2020
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialRichard G Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
Pageof 6